{
  "id": "mhgap#screening_cues_dec079ad",
  "content": "et al., 2022 (132 RCTs on comparative efficacy body weight, aripiprazole LAI did not.\nand tolerability of 32 oral and LAI antipsychotics – Prolactin: Paliperidone LAI seemed to increase\nfor the maintenance treatment of adults with prolactin, aripiprazole LAI did not.\nschizophrenia) (198).\ny Almost all LAIs compared with placebo had large Remarks\neffects for relapse prevention. Clopenthixol LAI was y The medicines included in the recommendation\nnot statistically significant compared with placebo, correspond to the WHO EML (13), including\nbut did outperform placebo in pairwise meta- both those that are currently included or being\nanalysis. In summary, there was not much difference considered for addition. The above recommendation\nbetween the several LAIs compared with placebo for is based on the context, availability and costs of\nrelapse prevention; they all showed large efficacy. using LAIs.\ny The results for overall symptoms and overall\nResearch gaps\nfunctioning were similar to those for the outcome\nrelapse (i.e. superiority of most LAIs over placebo; y Most of the evidence is from HICs.\nno clear evidence of differences between y More trials comparing second-generation LAI\nantipsychotics), but data were sparse. antipsychotics head-to-head are needed.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues et al., 2022 (132 RCTs on comparative efficacy body weight, aripiprazole LAI did not.\nand tolerability of 32 oral and LAI antipsychotics – Prolactin: Paliperidone LAI seemed to increase\nfor the maintenance treatment of adults with prolactin, aripiprazole LAI did not.\nschizophrenia) (198).\ny Almost all LAIs compared with placebo had large Remarks\neffects for relapse prevention. Clopenthixol LAI was y The medicines included in the recommendation\nnot statistically significant compared with placebo, correspond to the WHO EML (13), including\nbut did outperform placebo in pairwise meta- both those that are currently included or being\nanalysis. In summary, there was not much difference considered for addition. The above recommendation\nbetween the several LAIs compared with placebo for is based on the context, availability and costs of\nrelapse prevention; they all showed large efficacy. using LAIs.\ny The results for overall symptoms and overall\nResearch gaps\nfunctioning were similar to those for the outcome\nrelapse (i.e. superiority of most LAIs over placebo; y Most of the evidence is from HICs.\nno clear evidence of differences between y More trials comparing second-generation LAI\nantipsychotics), but data were sparse. antipsychotics head-to-head are needed. Et al., 2022 (132 rcts on comparative efficacy body weight, aripiprazole lai did not. and tolerability of 32 oral and lai antipsychotics – prolactin: paliperidone lai seemed to increase\nfor the maintenance treatment of a..."
}